Overview

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, single-arm, phase II clinical trial of Everolimus (RAD001) in patients with segmental overgrowth syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Jochen Roessler
Collaborator:
Clinical Trials Unit Freiburg
Treatments:
Everolimus
Sirolimus